Computational analysis demonstrates pH-dependent binding of therapeutic antibodies, indicating reduced cardiotoxicity risk.
Therapeutic antibodies face on-target/off-tumor toxicity, causing adverse effects such as cardiotoxicity, skin rashes, and organ inflammation. To mitigate these challenges, pH-dependent antibodies have been engineered to preferentially bind in the...
No takes yet. Share an insight, caveat, or question.
Destiarani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: